Applied Therapeutics reports FY24 EPS (76c), consensus ($1.33)

Reports FY24 revenue $455K, consensus $553k. Reports cash, cash equivalents of $79.4M as of December 31, 2024. “We remain focused on preparing for potential regulatory interactions regarding govorestat in both Classic Galactosemia and Sorbitol Dehydrogenase Deficiency,” said Les Funtleyder, Interim CEO and CFO of Applied Therapeutics (APLT). “As we continue to optimize our strategy for our late-stage programs, we have also made key senior appointments across regulatory, medical and quality affairs functions to bolster our capabilities. We are confident in the promise of govorestat across indications and remain committed to our mission of addressing the unmet needs of patients with rare diseases.”